Gortner L, Hilgendorff A
Abteilung für Neonatologie und Pädiatrische Intensivmedizin, Zentrum für Kinderheilkunde und Jugendmedizin der Justus-Liebig-Universität Giessen, Giessen.
Z Geburtshilfe Neonatol. 2004 Jun;208(3):91-7. doi: 10.1055/s-2004-819002.
Treatment of neonatal RDS in premature infants with intratracheal administration of natural surfactant has become gold standard therapy. Natural surfactant preparations mainly contain, apart from phospholipids, the surfactant associated proteins B and C (SP-B and SP-C). Both proteins are synthesized mainly in alveolar type-II cells and Clara-cells, SP-B, also in the gastrointestinal tract and the auditive tube. SP-B is encoded on chromosome 2 over a region with 11 exons, whereas the SP-C gene is localized on chromosome 8 in a region containing 6 exons. Transcription of both SP-B and SP-C is induced by TTF-1. Furthermore SP-1 and SP-3 are known as transcription factors for SP-B. The main function of SP-B and SP-C is to maintain physiologic surface properties enabeling adequate lung mechanics. A complete SP-B deficiency following homozygous mutations in the SP-B gene (e. g. 121-ins 2-mutation) therefore leads to severe respiratory failure postnatally, due to the lack of functional surfactant. On the other hand complete deficiency of SP-C causes chronic interstitial pneumonitis as well in infants as in adults depending on disease-modifiers yet unknown. Besides the surface tension lowering property, SP-B reveals immunological functions regarding its interaction with different proinflammatory cellular systems as well as other inflammatory mediators, e. g. following hyperoxia. For SP-C first studies have described modulation of inflammatory reactions in macrophages, suggesting similar immune-modulatory effects. Whereas basic effects on lung mechanisms of both lipophilic surfactant proteins seem to be well understood, their immunologic local pulmonary functions and effects on surfactant metabolism require further investigations.
气管内给予天然表面活性剂治疗早产儿新生儿呼吸窘迫综合征已成为金标准疗法。天然表面活性剂制剂除磷脂外,主要还含有表面活性剂相关蛋白B和C(SP-B和SP-C)。这两种蛋白主要在II型肺泡细胞和克拉拉细胞中合成,SP-B也在胃肠道和咽鼓管中合成。SP-B由位于2号染色体上一个有11个外显子的区域编码,而SP-C基因位于8号染色体上一个包含6个外显子的区域。SP-B和SP-C的转录均由TTF-1诱导。此外,SP-1和SP-3是已知的SP-B转录因子。SP-B和SP-C的主要功能是维持生理表面特性,以实现适当的肺力学功能。因此,SP-B基因纯合突变(例如121-ins 2-突变)导致的完全SP-B缺乏会在出生后导致严重呼吸衰竭,原因是缺乏功能性表面活性剂。另一方面,SP-C的完全缺乏在婴儿和成人中都会导致慢性间质性肺炎,这取决于尚不清楚的疾病修饰因子。除了降低表面张力的特性外,SP-B在与不同促炎细胞系统以及其他炎症介质相互作用时还具有免疫功能,例如在高氧情况下。对于SP-C,最初的研究已经描述了其对巨噬细胞炎症反应的调节作用,提示有类似的免疫调节作用。虽然这两种亲脂性表面活性剂蛋白对肺机制的基本作用似乎已得到充分了解,但其免疫局部肺功能以及对表面活性剂代谢的影响仍需要进一步研究。